AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1773272 — intervention group
Group type: EXPERIMENTAL
Intervention: 3F/wk and 5F/wk
Number of subjects: 734
Study 6895626 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate (1 g, 0.5 h before each meal and at bedtime)
Number of subjects: 59
Study 6895626 — intervention group
Group type: COMPARATOR
Intervention: cimetidine (300 mg, 0.5 h before each meal and at bedtime)
Number of subjects: 59
Study 29949505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (120 ml of vodka followed by 60 ml of vodka)
Number of subjects: 21
Study 29949505 — intervention group
Group type: COMPARATOR
Intervention: H2O (water)
Number of subjects: 21
Study 28444115 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm with more responders
Number of subjects: 0
Study 28444115 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 26118324 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infiltration into nasal packing
Number of subjects: 50
Study 26118324 — intervention group
Group type: COMPARATOR
Intervention: Saline infiltration into nasal packing
Number of subjects: 50
Study 23810812 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee brace uninflated
Number of subjects: 18
Study 23810812 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee brace inflated to 7 psi
Number of subjects: 18
Study 23810812 — intervention group
Group type: COMPARATOR
Intervention: No knee brace
Number of subjects: 18
Study 22159621 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 30
Study 19469683 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 0
Study 17121590 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP HFA 100 microg twice daily
Number of subjects: 24
Study 17121590 — intervention group
Group type: COMPARATOR
Intervention: BDP CFC 100 microg twice daily
Number of subjects: 24
Study 17121590 — intervention group
Group type: COMPARATOR
Intervention: BDP CFC 200 microg twice daily
Number of subjects: 24
Study 17121590 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BDP HFA 100 microg and BDP CFC 100 microg
Number of subjects: 24
Study 17121590 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-period comparisons of active treatments
Number of subjects: 24
Study 15085875 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 0
Study 15085875 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment and best supportive care
Number of subjects: 0
Study 11346432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DFMO at daily dosages between 0.075 and 0.4 g/m(2) for 12 months
Number of subjects: 123
Study 11346432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 9720660 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg qd p.o. for 4 consecutive days starting 2 days before immunization)
Number of subjects: 71
Study 9720660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 9720660 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 71
Study 9720660 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated vaccination
Number of subjects: 71
Study 9161249 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic anesthesia
Number of subjects: 21
Study 9161249 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia
Number of subjects: 21
Study 2929825 — intervention group
Group type: EXPERIMENTAL
Intervention: Injured knee (ACL tear)
Number of subjects: 11
Study 2929825 — intervention group
Group type: COMPARATOR
Intervention: Noninjured knee
Number of subjects: 11
Study 2929825 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control group
Number of subjects: 11
Study 4694690 — intervention group
Group type: EXPERIMENTAL
Intervention: New Lanoxin tablets
Number of subjects: 0
Study 4694690 — intervention group
Group type: COMPARATOR
Intervention: Old Lanoxin tablets
Number of subjects: 0
Study 6272242 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH‐1‐17 (Synchrodyn, Hoechst)
Number of subjects: 10
Study 6272242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30576772 — intervention group
Group type: EXPERIMENTAL
Intervention: BT-11 (300 mg daily)
Number of subjects: 121
Study 30576772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 29633238 — intervention group
Group type: EXPERIMENTAL
Intervention: vodka
Number of subjects: 16
Study 29633238 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 16
Study 27183377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 mg oral twice daily) plus pegylated interferon alfa‐2a (160 μg subcutaneous once weekly) plus ribavirin (1000–1200 mg/day) for 12 weeks
Number of subjects: 120
Study 27183377 — intervention group
Group type: COMPARATOR
Intervention: Standard of care therapy (pegylated interferon alfa‐2a plus ribavirin) for 12 weeks
Number of subjects: 120
Study 25363174 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgical repair
Number of subjects: 80
Study 25363174 — intervention group
Group type: COMPARATOR
Intervention: Rotation flap
Number of subjects: 80
Study 23058029 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and clavulanic acid
Number of subjects: 107
Study 23058029 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 107
Study 19462921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluroben 100 mg tablet
Number of subjects: 24
Study 19462921 — intervention group
Group type: COMPARATOR
Intervention: Originator product 100 mg tablet
Number of subjects: 24
Study 17993031 — intervention group
Group type: EXPERIMENTAL
Intervention: One daily varnish application (G1)
Number of subjects: 40
Study 17993031 — intervention group
Group type: EXPERIMENTAL
Intervention: Two daily varnish applications with a 15-minute interval (G2)
Number of subjects: 40
Study 17993031 — intervention group
Group type: EXPERIMENTAL
Intervention: Two daily varnish applications with a 5-hour interval (G3)
Number of subjects: 40
Study 17993031 — intervention group
Group type: COMPARATOR
Intervention: Control group (G4) - no varnish treatment
Number of subjects: 40
Study 14499023 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus electro-acupuncture (EA)
Number of subjects: 52
Study 14499023 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 52
Study 11054515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (500 mg, two tablets twice daily)
Number of subjects: 87
Study 11054515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 8685994 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 86
Study 8685994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 1547671 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% capsaicin cream
Number of subjects: 277
Study 1547671 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 277
Study 3856501 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 80 mg
Number of subjects: 12
Study 3856501 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 160 mg
Number of subjects: 12
Study 3856501 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 240 mg
Number of subjects: 12
Study 3856501 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 320 mg
Number of subjects: 12
Study 30603828 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 96
Study 30603828 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 96
Study 27097657 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care and participatory workplace intervention
Number of subjects: 150
Study 27097657 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 25889643 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX) 12.5 g or 15 g
Number of subjects: 58
Study 25889643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 25889643 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX)
Number of subjects: 58
Study 23757457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bleaching technique (CBT) - 35% hydrogen peroxide (HP) in-office followed by 6% HP at-home for 7 days
Number of subjects: 36
Study 23757457 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep bleaching technique (DBT) - 6% HP at-home for 7 days followed by CBT
Number of subjects: 36
Study 23757457 — intervention group
Group type: COMPARATOR
Intervention: Combined bleaching technique (CBT)
Number of subjects: 36
Study 23757457 — intervention group
Group type: COMPARATOR
Intervention: Deep bleaching technique (DBT)
Number of subjects: 36
Study 21860572 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser peripheral iridotomy (LPI)
Number of subjects: 24
Study 21860572 — intervention group
Group type: EXPERIMENTAL
Intervention: LPI plus iridoplasty
Number of subjects: 24
Study 18192039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pulse pressure in non-ischaemic heart failure patients
Number of subjects: 1901
Study 18192039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mean arterial pressure in ischaemic heart failure patients
Number of subjects: 1901
Study 18192039 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher NYHA class and lower pulse pressure in both ischaemic and non-ischaemic patients
Number of subjects: 1901
Study 18251240 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based total intravenous anesthesia (TIVA)
Number of subjects: 90
Study 18251240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEVO)
Number of subjects: 90
Study 18251240 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (DES)
Number of subjects: 90
Study 15519084 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoSoniX US
Number of subjects: 120
Study 15519084 — intervention group
Group type: COMPARATOR
Intervention: US alone
Number of subjects: 120
Study 11439420 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based prediction methods for interim analyses
Number of subjects: 0
Study 11439420 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian simulation scheme for predicting milestone times
Number of subjects: 0
Study 9222648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide treatment for approximately 10 years
Number of subjects: 2500
Study 9222648 — intervention group
Group type: COMPARATOR
Intervention: Not receiving tolbutamide (Control)
Number of subjects: 2500
Study 8215669 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of ceftriaxone
Number of subjects: 1031
Study 8215669 — intervention group
Group type: COMPARATOR
Intervention: 48-hour regimen of flucloxacillin and gentamicin
Number of subjects: 1031
Study 3327511 — intervention group
Group type: EXPERIMENTAL
Intervention: RFFIT
Number of subjects: 119
Study 3327511 — intervention group
Group type: EXPERIMENTAL
Intervention: EIA-V
Number of subjects: 119
Study 3327511 — intervention group
Group type: EXPERIMENTAL
Intervention: EIA-P
Number of subjects: 119
Study 3327511 — intervention group
Group type: EXPERIMENTAL
Intervention: IFI
Number of subjects: 119
Study 31420055 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg) + Oxycodone (10 mg)
Number of subjects: 1226
Study 31420055 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (650 mg) only
Number of subjects: 1226
Study 29415828 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus cereus A 05 (4 vials with 5 mL × 10^6 every 6 hours)
Number of subjects: 58
Study 29415828 — intervention group
Group type: COMPARATOR
Intervention: Soluble fiber (10 g every 8 hours)
Number of subjects: 58
Study 25153575 — intervention group
Group type: EXPERIMENTAL
Intervention: l-thyroxine (l-T4) supplementation at a dose of 5 μg/kg/day
Number of subjects: 70
Study 25153575 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no l-T4 supplementation)
Number of subjects: 70
Study 23895024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0
Study 23895024 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 20890243 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone for 3 days postoperatively (Group 1)
Number of subjects: 60
Study 20890243 — intervention group
Group type: COMPARATOR
Intervention: No systemic steroid treatment (Group 2)
Number of subjects: 60
Study 19372328 — intervention group
Group type: EXPERIMENTAL
Intervention: TDS + OND
Number of subjects: 620
Study 19372328 — intervention group
Group type: COMPARATOR
Intervention: OND alone
Number of subjects: 620
Study 17132307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation for incontinence
Number of subjects: 23
Study 17132307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation for constipation
Number of subjects: 23
Study 17132307 — intervention group
Group type: COMPARATOR
Intervention: Placebo effect
Number of subjects: 23
Study 17132307 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic stimulation
Number of subjects: 23
Study 14982551 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fluoxetine (60 mg)
Number of subjects: 989
Study 14982551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for smoking cessation
Number of subjects: 989
Study 14982551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study 11368986 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed structured pretreatment counseling about hormonal effects of the injectable
Number of subjects: 350
Study 11368986 — intervention group
Group type: COMPARATOR
Intervention: Routine counseling
Number of subjects: 350
Study 9572066 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (5 grams intravenously over 2 hours, twice daily for 5 consecutive days; 10 grams in 1500 ml cardioplegia administered through the aortic root after aortic cross-clamping)
Number of subjects: 38
Study 9572066 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 38
Study 9572066 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 38
Study 10150550 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled sedation with midazolam
Number of subjects: 40
Study 10150550 — intervention group
Group type: COMPARATOR
Intervention: Empirical sedation with midazolam
Number of subjects: 40
Study 10150550 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion
Number of subjects: 40
Study 10150550 — intervention group
Group type: COMPARATOR
Intervention: Morphine plus diazepam
Number of subjects: 40
Study 10150550 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study 3072178 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal biofeedback (TBF)
Number of subjects: 59
Study 3072178 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (AT)
Number of subjects: 59
Study 3072178 — intervention group
Group type: COMPARATOR
Intervention: Self-relaxation control condition
Number of subjects: 59
Study 27654496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for child PTSD
Number of subjects: 47
Study 26727041 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (500 mg twice daily)
Number of subjects: 165
Study 26727041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 26727041 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone
Number of subjects: 165
Study 25523407 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (fluid, with and without dobutamine)
Number of subjects: 204
Study 25523407 — intervention group
Group type: COMPARATOR
Intervention: Standardised care (control)
Number of subjects: 204
Study 25523407 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oxygen delivery achievement (irrespective of intervention)
Number of subjects: 204
Study 25523407 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Number of subjects: 204
Study 23697610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention (n = 19,541)
Number of subjects: 48835
Study 23697610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention (n = 19,541) among women with higher baseline fat intake
Number of subjects: 48835
Study 23697610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention (n = 19,541) among women with lower baseline fat intake
Number of subjects: 48835
Study 23697610 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n = 29,294)
Number of subjects: 48835
Study 22114899 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscucin® Populi (IP) strength G (0.25%)
Number of subjects: 71
Study 22114899 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscucin® Populi (IP) strength H (5%)
Number of subjects: 71
Study 22114899 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscum Mali (VM) 2%
Number of subjects: 71
Study 22114899 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic solution)
Number of subjects: 71
Study 18609065 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (BK) group received 25 microg bradykinin infusion for 7 minutes before cardiopulmonary bypass (CPB)
Number of subjects: 41
Study 18609065 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 16978276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) for 14 weeks
Number of subjects: 97
Study 16978276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 97
Study 14677514 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunted hydrocephalus (HCP)
Number of subjects: 30
Study 14677514 — intervention group
Group type: COMPARATOR
Intervention: Cardiac (control)
Number of subjects: 30
Study 10996351 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 13
Study 10996351 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 13
Study 9388514 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy and radiotherapy
Number of subjects: 0
Study 9388514 — intervention group
Group type: EXPERIMENTAL
Intervention: Early use of radiotherapy
Number of subjects: 0
Study 9388514 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 0
Study 9388514 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and radiotherapy
Number of subjects: 0
Study 9388514 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy before surgical resection
Number of subjects: 0
Study 9388514 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy followed by surgery
Number of subjects: 0
Study 9388514 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of new drugs and radiotherapy
Number of subjects: 0
Study 2286468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 g single oral dose)
Number of subjects: 386
Study 2286468 — intervention group
Group type: COMPARATOR
Intervention: Pipemidic acid (400 mg twice daily for five days)
Number of subjects: 386
Study 7013868 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy protocol combining adriamycin (40 mg/m2 on day 1), vincristine (1.2 mg/m2 on day 2), cyclophosphamide (400 mg/m2 on days 3, 4, 5), 5 fluorouracil (500 mg/m2 on days 3, 4, 5) followed by cyclophosphamide (100 mg/m2/day for 7 days), melphalan (2.5 mg/m2/day for 7 days), methotrexate (25 mg/m2/week for 3 weeks) with 3 applications of living BCG
Number of subjects: 144
Study 7013868 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy protocol without BCG
Number of subjects: 144
Study 30708074 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 J escalating to 360 J
Number of subjects: 738
Study 30708074 — intervention group
Group type: COMPARATOR
Intervention: Fixed 360 J
Number of subjects: 738
Study 27677853 — intervention group
Group type: EXPERIMENTAL
Intervention: Climate change cue
Number of subjects: 1050
Study 27677853 — intervention group
Group type: EXPERIMENTAL
Intervention: Global warming cue
Number of subjects: 1050
Study 27677853 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit cue
Number of subjects: 1050
Study 27677853 — intervention group
Group type: COMPARATOR
Intervention: Control (no message)
Number of subjects: 1050
Study 26546067 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHD-CARE intervention (group psychosocial intervention delivered during eight 90-minute weekly sessions)
Number of subjects: 0
Study 26546067 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study 23949834 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 68
Study 23949834 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 68
Study 21914905 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim training (DS‐ST) for 12 weeks
Number of subjects: 28
Study 21914905 — intervention group
Group type: COMPARATOR
Intervention: Control group (DS‐NT)
Number of subjects: 28
Study 19170666 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 430
Study 19170666 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 430
Study 19170666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 16449211 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 1 week (group B)
Number of subjects: 40
Study 16449211 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (group A)
Number of subjects: 40
Study 15518024 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced use of third-generation cephalosporins (TGCs) after intervention (April to August 2003)
Number of subjects: 88
Study 15518024 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced use of third-generation cephalosporins (TGCs) after intervention
Number of subjects: 88
Study 15518024 — intervention group
Group type: COMPARATOR
Intervention: Prior exposure to third-generation cephalosporins (TGCs)
Number of subjects: 88
Study 11772156 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase-containing ointment (Novuxol)
Number of subjects: 24